Financière de Tubize SA Allée de la Recherche 60 1070 Brussels BE 0403.216.429

EU-IFRS FINANCIAL STATEMENTS

1.	1.1. 1.2. 1.3.	eral information Identification Board of directors Statutory auditor Activities and mission	61 61 61 61
2.	2.1. 2.2. 2.3.	ncial statements Statement of financial position Statement of profit or loss and other comprehensive income Statement of changes in equity Statement of cash flows	62 62 63 64
3.	3.1.	Basis of preparation of the financial statements Summary of significant accounting policies	65
		3.2.1. Equity accounting of the participating interest in UCB 3.2.2. Bank borrowings	65 66
		3.2.3. Cash flow hedges	66
		3.2.4. Income taxes	67
		3.2.5. Significant accounting policies UCB	67
		Judgements, accounting estimates and assumptions	67
		Initial application of amended standards	67
	3.5.	Impact of future application of issued new standards	68
4.	Note		
	4.1.	Participating interest in UCB	
		4.1.1. Carrying value	69
		4.1.2. Share of other comprehensive income	69
		4.1.3. Fair value	69
		4.1.4. Concert 4.1.5. Condensed financial information of UCB	69 70
	4.2	Financial instruments	70
	1.2.	4.2.1. Financial instruments by category	70
		4.2.2. Risks related to financial instruments	70
		4.2.3. Fair value of financial instruments	71
		4.2.4. Prepayments	71
		4.2.5. Cash and cash equivalents	72
		4.2.6. Bank borrowings	72
		4.2.7. Derivatives	74
	4.2	4.2.8. Other creditors	75
	4.3.	Income taxes 4.3.1. Deferred income tax assets and liabilities	75
		4.3.2. Relationship between tax expense and accounting profit	75
	4 4	General and administrative expenses	76
		Earnings per share	76
		Dividends	76
		Capital management	76
		Related parties' transactions	77

The EU-IFRS financial statements of Financière de Tubize for the financial year ended 31 December 2018 have been established by a resolution of the board of directors of 27 February 2019 and will be communicated to the general shareholders meeting of 24 April 2019.

1. General information

1.1. Identification

NAME: Financière de Tubize

Legal form: Public Limited Company

Address: Allée de la Recherche 60, 1070 Anderlecht, Belgium Register of legal persons – Commercial Court of Brussels

Website: http://www.financiere-tubize.be

Company number BE 0403 216 429

EU-IFRS FINANCIAL STATEMENTS to be communicated to the general meeting of 24/04/2019

Period from 01/01/2018 au 31/12/2018

Prior period from 01/01/2017 au 31/12/2017

1.2. Board of Directors

François Tesch, chairman of the board of directors, Route de Bettembourg 45 boîte A, L-1899 Luxembourg

Vauban NV (BE 0338.114.246), member of the board of directors, Rue Ducale 47-49, B-1000 Bruxelles, represented by Gaëtan Hannecart

Marc Speeckaert, member of the board of directors, avenue Albert 201, B-1190 Forest Cyril Janssen, member of the board of directors, Rue des Mélèzes 29, B-1150 Ixelles

Charles-Antoine Janssen, member of the board of directors, Claire Colline, Chaussée de Bruxelles 110, B-1310 La Hulpe

Nicolas Janssen, member of the board of directors, Avenue Ernest Solvay 108, B-1310 La Hulpe Evelyn du Monceau, member of the board of directors, Avenue des Fleurs 14, B-1150 Woluwé-Saint-Pierre

Fiona de Hemptinne, member of the board of directors, Fairlawn Grove 20, W4 5EH London, UK Cédric van Rijckevorsel, member of the board of directors, Chipstead Street 37, SW6 3S3 London, UK Cynthia Favre d'Echallens, member of the board of directors, Route d'Ottignies 74A, B-1380 Lasne

1.3. Independent Auditor

Mazars Réviseurs d'Entreprises SCRL (BE 0428 837 889), statutory auditor (IRE register n° B00021), Avenue Marcel Thiry 77/4, B-1200 Woluwé-Saint-Lambert, represented by Xavier DOYEN (IRE register n° A01202)

1.4. Activities and mission

Financière de Tubize (the "Company") is a mono-holding company, listed on Euronext Brussels under the ISIN code TUB BE0003823409, that holds and manages a participating interest of 68,076,981 UCB shares, representing 35.00% of the total shares issued by UCB, a biopharmaceutical company domiciled in Belgium whose shares are also listed on Euronext Brussels. Financière de Tubize is the reference shareholder of UCB.

The mission of Financière de Tubize is to create long term value for its shareholders by supporting, as a stable reference shareholder, the maximisation of UCB's potential and a sustainable growth of its industrial project.

For information about UCB: www.ucb.com

Cyril Janssen Evelyn du Monceau
Member of the board of directors Member of the board of directors

2. Financial statements

2.1. Statement of financial position

€ 000			
31 December	Notes	2018	2017
Participating interest in UCB	4.1.1.	2.481.939	2.309.844
Non-current assets		2.481.939	2.309.844
Prepayments	4.2.4.	31	33
Other receivables		102	-
Cash and cash equivalents	4.2.5.	1.529	1.452
Current assets		1.662	1.485
Assets		2.483.601	2.311.329
Equity		2.339.563	2.115.676
Bank borrowings	4.2.6.	90.000	140.000
Derivatives	4.2.7.	318	741
Non-current liabilities		90.318	140.741
Bank borrowings	4.2.6.	52.613	52.144
Derivatives	4.2.7.	571	2.252
Other creditors	4.2.8.	536	516
Current liabilities		53.720	54.912
Liabilities		144.038	195.652
Province of All All Marie		2.402.604	2 244 222
Equity and liabilities		2.483.601	2.311.329

2.2. Statement of profit or loss and other comprehensive income

€000	Notes	2018	2017
Profit or Loss			
Share of profit of UCB		288,521	272,233
Borrowing cost	4.2.6.	-2,144	-5,118
General and administrative expenses	4.4.	-951	-941
Profit before tax		285,156	266,174
Income tax	4.3.2.	-	19,760
Profit		285,156	285,934
OTHER COMPREHENSIVE INCOME			
Share, after tax, of other comprehensive income of UCB		-35,702	-88.661
Those that will not be reclassified to profit or loss	4.1.2.	3,203	3,288
Those that will be reclassified subsequently to profit or loss when certain	1.1.2.	5,205	3,200
conditions are met	4.1.2.	-38,905	-91,949
Other items, after tax, of other comprehensive income, after tax, that will be	1.1.2.	30,703	71,717
reclassified subsequently to profit or loss when certain conditions are met		738	1,583
Cash flow hedges	4.2.7.	738	1.583
Other comprehensive income		-34,964	-87,078
		0.00.400	400.086
COMPREHENSIVE INCOME		250,192	198,856
Profit attributable to			
Non-controlling interests		-	-
Owners of the parent		285,156	285,934
Comprehensive income attributable to			
Non-controlling interests			
Owners of the parent		250,192	198,856
Owners of the parent		250,192	198,850
Earnings per share (in €)			
Basic and diluted	4.5.	6.40	6.42

2.3. Statement of changes in equity

	Capital and share premium	Retained earnings	Treasury shares	Other reserves	Translation adjustments	Assets held for sale	Cash flow hedges	Total equity
Balance at								
01/01/2018	236,225	2,108,415	-130,844	-56,459	-79,463	10,629	27,173	2,115,676
Dividends		-24,056						-24,056
Comprehensive income			-2,124					
- Profit		285,156						285,156
- Share of other comprehensive income of UCB				3,203	24,587	-12,643	-50,849	-35,702
 Cash flow hedges 								-
– Reclassification adjustment								
Share of other changes of net assets of UCB								
 Share based payments 		21,049						21,049
– Transfer between reserves		-19,093	19,093					-
– Treasury shares			-13,410					-13,410
		1.956	5,683					7.639
Changes in the number of own shares held by UCB		-8,581	477	208	293	-39	-122	-7.763
Balance at		-8,581	4//	208	293	-39	-122	-7,703
31/12/2018	236,225	2,362,890	-126,808	-53,048	-54,583	-2,053	-23,060	2,339,563

	Capital and share premium	Retained earnings	Treasury shares	Other reserves	Translation adjustments	Assets held for sale	Cash flow hedges	Total equity
Balance at 01/01/2017	236,225	1,833,036	-102,256	-59,596	47,726	15,099	-12,679	1,957,555
Dividends		-23,165						-23,165
Comprehensive income								
– Profit		285,934						285,934
 Share of other comprehensive income of UCB 				3,288	-127,308	-4,509	39,868	-88,661
– Cash flow hedges		1,030						1,030
 Reclassification adjustments 		553						553
		287,517	-	3,288	-127,308	-4,509	39,868	198,856
Share of other changes in net assets of UCB								
– Share based payments		23,155						23,155
 Transfer between reserves 		-17,383	17,383					_
– Treasury shares			-45,715					-45,715
		5,772	-28,332	-	-			-22,561
Changes in the percentage of the participating interest in UCB		5,258	-257	-150	120	38	-17	4,991
Balance at 31/12/2017	236,225	2,108,415	-130,844	-56,459	-79,463	10,629	27,173	2,115,676

2.4. Statement of cash flows

€ 000	Notes	2018	2017
Directors remuneration & attendance fees		-406	-377
Remuneration general manager		-96	-161
Statutory auditor's fee		-12	-6
Professional services fees		-161	-53
Contributions		-125	-113
Payment of services		-86	-91
Payment of expenses		-52	-9
Gift		-20	-25
Advances		-	-
Indirect taxes		-102	-70
Cash flows from operating activities		-1,060	<i>-905</i>
Dividends received		80,331	78,289
Cash flows from investing activities		80,331	78,289
Dividends paid		-24,056	-23,165
Interests and commissions paid		-3,514	-4,422
Reimbursement of bank borrowings		-53,000	-152,000
Drawings from the confirmed lines		3,500	103,000
Payment dividends prior years			-6
Repurchase of own shares		-2,124	-
Cash flows from finance activities		-79,194	-76,593
Takal anali Garan		7.7	701
Total cash flows	425	77	791
Cash and cash equivalents beginning of period	4.2.5.	1,452	662
Cash and cash equivalents end of period	4.2.5.	1,529	1,452

See also Note 4.2.6. with respect to disclosures required by Amendments to IAS 7: Disclosure initiative.

3. Accounting policies

3.1. Basis of preparation of the financial statements

To provide a useful and complete set of information to the market, the Company prepares, in addition to the annual accounts established in accordance with the Company Code and Belgian accounting law (BE GAAP), financial statements in accordance with international financial reporting standards as adopted by the European Union (EU-IFRS), with equity accounting of UCB.

The EU-IFRS financial statements are prepared on a historical cost basis, except for derivative financial instruments that are measured at fair value.

Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between willing parties at the measurement date.

The Company uses valuation techniques to measure fair values, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All inputs to measure fair value are categorised within one of the following levels:

Level 1 – quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 – directly or indirectly observable inputs, other than those of level $1\,$

Level 3 – unobservable inputs.

For assets and liabilities that are measured at fair value on a recurring basis, the Company determines at each reporting date when transfers, if any, have occurred between levels in the hierarchy.

For the purpose of fair value disclosures (note 4.2.3.), the Company has determined classes of assets and liabilities on the basis of the items disclosed on the face of the statement of financial position.

Current / non-current classification

An asset is current when it is cash or cash equivalents, or when it is expected to be realised within twelve months after the reporting date. All other assets are classified as non-current.

A liability is current when it is expected to be settled within twelve months after the reporting date, or when it is due to be settled within twelve months after the reporting date and the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the end of the reporting period. All other liabilities are classified as non-current.

Deferred taxes are always classified as non-current.

3.2. Summary of significant accounting policies

3.2.1. Equity accounting of UCB

The Company having significant influence over UCB, the latter is considered to be an associated company as defined in IAS 28. Consequently, the investment in UCB is accounted for using the equity method.

The equity method is a method of accounting whereby the investment in UCB is initially recorded at cost and adjusted thereafter for the post acquisition change in the Company's share of the net assets of UCB.

Cost comprises either the acquisition price (the purchase price and any expenditures that are directly attributable to the acquisition), or the contribution value. Any excess of the cost of the investment over the Company's share of the net fair value of UCB's identifiable assets and liabilities (goodwill) is included in the carrying amount of the investment. When the Company acquires an additional interest in UCB whereby UCB continues to be an associate, the cost of acquiring the additional interest is added to the existing carrying amount of the participating interest. The increase in the participating interest is split between goodwill and the additional interest in the fair value of the net assets of UCB at the date of the increase of the participating interest. The existing goodwill is not re-measured.

A change in the Company's share of the net assets of UCB occurs when there is a change in the percentage of the participating interest of the Company in UCB ("change of type 1"), or, without a change in the percentage of the participating interest of the Company in UCB, when there is a change in the net assets of UCB that is attributable to Financière de Tubize ("change of type 2"). The impact of a type 1 change is recorded in the statement of changes in equity. The impact of a type 2 change is recorded as follows: the Company's share of UCB's profits or losses is recognised in profit or loss in the statement of profit or loss and other comprehensive income; its share of UCB's other comprehensive income is recognised in other comprehensive income in the statement of profit or loss and other comprehensive income; and its share of other changes in the net assets of UCB is recognised in the statement of changes in equity. The cumulative post acquisition movements adjust the carrying amount of the participating interest. Distributions received from UCB reduce the carrying amount of the participating interest.

After application of the equity method, whenever there is any objective indication that the participating interest may be impaired, the Company performs an impairment test by comparing the carrying amount of the participating interest (including goodwill which is not tested for impairment separately) with its recoverable amount (the higher of value in use and fair value less costs to sell). If the recoverable amount is lower than the carrying amount, an impairment loss equal to the difference between both amounts is recorded as a loss in the statement of profit or loss.

3.2.2. Bank borrowings

Bank borrowings are initially measured at the cash obtained, net of directly attributable transaction costs.

They are subsequently measured at amortised cost using the effective interest method with gains and losses recognised in profit or loss when the debt is derecognised as well as through the amortisation process.

Bank borrowings, or part of it, are derecognised when they are extinguished, that is, when the obligation specified in the borrowing contract is (partly) discharged by paying the bank.

Debt restructuring is accounted for as an extinguishment of the original debt and the recognition of a new debt, only if the terms of the debt have substantially changed, which is the case if the net present value of the cash flows under the new terms (including any fees and costs incurred) discounted at the original effective interest rate is at least 10% different from the discounted present value of the remaining cash flows of the original debt. If the restructuring is accounted for as an extinguishment of the original debt, the difference between the carrying amount of the original debt and the fair value of the new debt assumed, as well as any fees and costs incurred, are recognised in profit or loss at the date of extinguishment. If the restructuring is not accounted for as an extinguishment, the carrying value of the original debt, net of fees and costs incurred, is treated as the new basis for amortised cost accounting, using the new effective interest rate; fees and costs incurred as part of the restructuring are thus amortised over the remaining term of the restructured debt according to the effective interest method.

Borrowings are classified as current liabilities unless there is an unconditional right to defer settlement of the liability for at least twelve months after the balance sheet date.

3.2.3. Cash flow hedges

The Company uses interest rate swaps (including deferred start swaps) to hedge (part of) its exposure to cash flow risks arising from variable rate bank borrowings. The Company documents, both at hedge inception and on an on-going basis, that the interest rate swaps are highly effective in offsetting changes in cash flows of the hedged bank borrowings.

The interest rate swaps that have passed the effectiveness test and have been designated as hedging instrument, are initially recorded at fair value and attributable transaction costs are recognised in profit or loss when incurred. The interest rate swaps are subsequently re-measured at fair value. The effective portion of changes in the fair value of the interest rate swaps is recognised in other comprehensive income. The gain or loss relating to the ineffective portion, if any, is recognised immediately in profit or loss.

A cash flow hedge relationship is discontinued prospectively if the hedge fails the effectiveness test, the hedging instrument is sold or terminated, or management revokes the hedge designation. As from the date of discontinuation of the hedge relationship, changes in fair value of the swap are recorded in profit or loss, and the accumulated balance of the clean price at that date, is accounted for as follows: (i) the portions of the hedging that correspond to cash flows that are no longer expected to occur (over-hedging) are reclassified from equity to profit or loss of the period during which the discontinuation has occurred, and (ii) the remaining balance is reclassified from equity to profit or loss over the remaining lifetime of the swap based on the time weighted notional amounts.

The allocation of the clean price of the interest rate swaps between current and non-current is based on the time weighted notional amounts. The interest accruals are classified as current.

Accrued interest payable and receivable on the same swap are offset in the statement of financial position. Such offsetting equally applies to interest income and interest expenses in the statement of profit or loss.

3.2.4. Income taxes

Income tax expenses or credits comprise current and deferred income taxes. They are recognised in profit or loss except to the extent that they relate to items recognised in other comprehensive income, in which case the tax expenses or credits are recognised in other comprehensive income.

Current income taxes are calculated on the basis of the tax laws enacted or substantially enacted in Belgium at the balance sheet date.

Deferred income taxes are calculated on temporary differences between the carrying amounts of assets and liabilities and their corresponding tax bases. Deferred income tax liabilities are generally recognised for all taxable temporary differences and deferred income tax assets are recognised to the extent it is probable that future taxable profits will be available against which deductible temporary differences, carried forward tax credits or carried forward tax losses can be utilised.

The carrying amount of deferred income tax assets is reviewed at each balance sheet date and reduced to the extent it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred income taxes are calculated at the tax rates that are expected to apply in the period when the liability is settled, or the asset realised. Deferred tax assets and liabilities are not discounted.

Deferred income tax assets and liabilities are only offset if the Company has a legally enforceable right to offset current tax liabilities and assets and the deferred income taxes relate to the same taxable entity and the same taxation authority.

Deferred income tax assets and liabilities are classified as non-current.

3.2.5. Significant accounting policies UCB

Reference is also made to UCB's summary of significant accounting policies; through the equity method of accounting they do impact the Company's financial position and results.

3.3. Judgements, accounting estimates and assumptions

The preparation of the consolidated financial statements requires the board of directors to make judgments, accounting estimates and assumptions that affect the reported assets and disclosures. Where applicable, such judgments, estimates and assumptions are explained in the relevant notes.

3.4. Initial application of amended standards

During this accounting period, the Company applied all new or revised standards or interpretations as issued by the International Accounting Standards Board (IASB) and by the International Financial Reporting Interpretations Committee (IFRIC) of the IASB, to the extent that they are relevant to its activities and applicable for the accounting period starting January 1, 2018. The Company has not applied anticipatively neither new Standards nor Interpretations for which the mandatory applicable date is subsequent to December 31, 2018.

The following Standards, Interpretations and Amendments, as issued by the IASB or IFRIC, are in force since this accounting period:

- Annual improvements to IFRS Standards 2014-2016 cycle (applicable as from 1/1/2018). The Company does not expect any impact from these annual improvements;
- Amendments to IAS 12 "Income Tax": Recognition of deferred tax assets for unrealised losses. The company having no unrealised losses, these amendments are not applicable;
- Amendments to IFRS 4 Insurance Contracts Applying IFRS 9 Financial Instruments with IFRS 4 Insurance Contracts. The standard dealing with insurance contracts is not applicable to the Company;
- IFRS 15 Revenue from Contracts with Customers and Clarifications to IFRS 15 Revenue from Contracts with Customers. The Company does not derive any revenue from contracts with customers and accordingly the Company will not be impacted by this standard;
- IFRS 9 Financial Instruments. The Company has financial instruments in place (borrowings and derivatives). However, considering the current accounting practices of the Company, the application of IFRS 9 will not have any impact.
- IFRIC 22 Foreign Currency Transactions and Advance Consideration. This interpretation will not impact the Company considering that there is no transactions in foreign currencies;
- Amendments to IAS 40 Transfers of Investment Property (applicable as from 1/1/2018). These amendments do not apply to the Company as the Company has no investment property;

3.5. Impact of future application of issued new standards

New IFRS standards or interpretations that have been issued by the IASB or IFRIC but are not yet mandatorily applicable in 2018 are discussed hereafter. If relevant, the Company will adopt these texts when they become mandatory. Reference is also made to UCB's note on the subject who anticipatively adopted 'IFRS 16: leases' norms. Through the equity method of accounting, the Company's financial position and results will be impacted for its ownership interest in UCB. It relates to the following texts:

Texts endorsed by EFRAG:

- IFRS 16 Leases (applicable as from 1/1/2019). The Company is not a party to any lease agreement and accordingly the application of this standard will not impact the Company;
- IFRIC 23 Uncertainty over Income Tax Treatments (applicable as from 1/1/2019). The Company does not anticipate any impact from the application of this interpretation;
- Amendments to IFRS 2 Classification and measurement of share-based payment transactions (applicable as from 1/1/2018). This amendment should not impact the Company considering the absence of share-based payment transaction;
- Amendments to IFRS 9 Prepayment features with negative compensation (applicable as from 1/1/2019). These amendments will not impact the Company as it does not enter into transactions scoped by these amendments;
- Amendments to IAS 28 Long-term Interests in Associates and Joint Ventures (applicable as from 1/1/2019). These amendments address the impairment of interests in associates or joint ventures. The application of these amendments should not impact the Company as there is no impairment indicator of the interest of the Company in UCB;

Texts not yet endorsed by EFRAG:

- IFRS 17 Insurance Contracts (applicable as from 1/1/2021). This standard is not applicable to the Company;
- In February 2018, the IASB also published amendments to IAS 19 standard, dealing with employee benefits. As the Company has no employee, the application of these amendments will not impact the Company;
- Annual Improvements to IFRS Standards 2015 2017 Cycle (applicable as from 1/1/2019). No impact is expected from these annual improvements;
- Amendments to references to the IFRS conceptual framework (applicable as from 1/1/2020);
- Amendments to IFRS 3 Business Combinations (applicable as from 1/1/2020);

- Amendments to IAS 1 and IAS 8 Definition of metrial (applicable as from 1/1/2020);

4. Notes

4.1. Participating interest in UCB

4.1.1. Carrying value

	Share of the net assets of UCB		Goo	dwill	Total	
€ 000	2018	2017	2018 2017		2018	2016
At 1 January	2,102,405	2,014,691	207,439	207,439	2,102,405	2,258,543
Distribution	-80,331	-78,289	-	-	-80,331	-78,289
Share of the profit of UCB	288,251	272,233	-	-	288,251	272,233
Share of other comprehensive income of UCB (note 4.1.3.)	-35,702	-88,661	-	-	-35,702	-88,661
Share of other changes in net assets of UCB ¹	7,640	-22,561	-	-	7,640	-22,561
Changes in the percentage of participating interest as a result of changes in the number of own shares held by UCB	-7,763	4,991	-	-	-7,763	4,991
At 31 December	2,274,500	2,102,405	207,439	207,439	2,439,939	2,309,844

 $^{^{\}mbox{\tiny 1}}$ See the statement of changes in equity for a breakdown by item of net assets

4.1.2. Share of other comprehensive income of UCB

		2018			2017	
€ 000	Gross	Tax	Net	Gross	Tax	Net
Items that will not be reclassified to profit or loss						
- Re-measurement of defined benefit obligations	4,520	-1,317	3,203	9,758	-6,470	3,288
	4,520	-1,317	3,203	9,758	-6,470	3,288
Elements that may be reclassified subsequently to						
profit or loss	-38,905	-	-38,905	-91,949	-	-91,949
- Translation adjustment	24,587	-	24,587	-127,308	-	-127,308
- Net result from available-for-sale financial assets	-12,643		-12,647	-4,509		-4,509
- Effective portion of cash flow hedges	-50,849	-	-50,849	39,868	-	39,868
		-			-	
Share of other comprehensive income of UCB	-34,385	-1,317	-88,661	-82,191	-6,470	-88,661

4.1.3. Fair value

31 December	2018	2017
Number of UCB shares	68,076,981	68,076,981
Share price UCB (€)	71,3	66.18
Fair value of the participating interest in UCB (€ 000)	4,853,889	4,505,335
Carrying value (€ 000)	2,481,939	2,309,844
Excess of fair value over carrying value	2,371,950	2,195,491

4.1.4. Concert

	Number of v	oting rights	% of voting rights		
31 December	2018	2017	2018	2017	
Financière de Tubize	68,076,981	68,076,981	35.00	35.00	
Schwarz Vermögensverwaltung	0	2,021,404	0	1.04	
Total	68,076,981	70,098,385	35,00	36.04	

On January 19, 2018, the Company received from Schwarz Vermögensverwaltung the confirmation of the ending of the concert agreement. In accordance with Article 14 of the Law of May 2, 2007, the Company made a transparency declaration to UCB on January 25, 2018.

4.1.5. Summarised financial information about UCB

Summarised statement of financial position

€ 000 000		
31 December	2018	2017
Non-current assets	7,564	7,240
Current assets	2,950	2,677
Non-current liabilities	-2,021	-2,213
Current liabilities	-2,238	-1,950
Net assets	6,255	5,736
Non-controlling interests	-54	-77
Net assets attributable to UCB shareholders	6,309	5,813

Summarised statement of comprehensive income

€ 000 000	2018	2017
Revenue	4,632	4,530
Profit from continuing operations	915	770
Profit from discontinued operations	8	1
Other comprehensive income	-102	-233
Comprehensive income	721	538

Reconciliation of summarised financial information to carrying value

€ 000 000		
31 December	2018	2017
Net assets attributable to UCB shareholders	6,309	5,813
Interest of the Company ²	36.0370%	36.1706%
Company's share of net assets of UCB	2,275	2,103
Goodwill on acquisition	207	207
Carrying value of participating interest in UCB	2,482	2,310

4.2. Financial instruments

4.2.1. Financial instruments by category

€ 000	Loans & Ro	ns & Receivables Liab		Liabilities at amortised cost		atives
31 December	2018	2017	2018	2017	2018	2017
Prepayments	31	33	-	-	-	-
Other receivables	102	_	-			
Cash & cash equivalents	1,529	1,452	-	-	-	-
Bank borrowings	-	-	-142,613	-192,144	-	-
Derivatives	-	-	-	-	-889	-2,993
Other creditors	-	-	-536	-516	-	-
Total	1,662	1,485	-143.149	-192,660	-889	-2,993

4.2.2. Risks related to financial instruments

The Company is exposed to interest rate risk resulting from fixed rate bank borrowings. The risk is monitored through periodic calculations of the fair value of these borrowings. The fair values at 31 December 2018 of these borrowings are disclosed in note 4.2.3.

The Company is exposed to cash flow risk resulting from floating rate bank borrowings. The Company can make use of interest rate swaps (including deferred start swaps) to protect itself against the risk of an increase of interest rates. The Company permanently follows the developments on the interest rate markets and takes hedging initiatives in function of its assessment of the risks. The situation of the bank borrowings and their hedging as at 31 December 2018 is reflected in the notes 4.2.6. and 4.2.7.

The Company is exposed to liquidity risk, in particular the risk of facing difficulties in meeting its obligations under the bank borrowings. The contractual maturities of these borrowings are summarised in note 4.2.6. The Company considers that the dividend flow from UCB and, to the extent necessary, new credit recourse will ensure that today's contractually scheduled reimbursements be met.

The Company is exposed to credit risk to the extent a bank-counterparty to cash at bank or to interest rate swaps would not meet its obligations and the Company, as a result thereof, would incur a financial loss. The bank-counterparties are Belgian banks with a rating of 'upper medium grade'.

 $^{^*}$ When calculating the percentage, the 5,828,462 own shares held by UCB as at 31/12/2016 are excluded from the denominator

4.2.3. Fair value of financial instruments

Set out below is a comparison, by class, of the carrying amounts and the fair values of the Company's financial instruments:

€ 000	Level of the inputs in the fair value Carrying values		Fair	values	
31 December	hierarchy	2018	2017	2018	2017
Prepayments	-	31	33	31	33
Other receivables	2	102	-	102	-
Cash and cash equivalents	-	1,529	1,452	1,529	1,452
Bank borrowings	2	-142,613	-192,144	-142,613	-192,144
Derivatives	2	-889	-2,993	-889	-2,993
Other creditors	-	-536	-516	-536	-516

The fair value of prepayments, cash and cash equivalents, suppliers and other creditors approximates the carrying amount because of the short-term maturities of these instruments.

The fair value of floating rate bank borrowings approximates the carrying value because the floating rates reflect the short-term market rates.

The Company uses a present value technique to determine the fair value of its fixed rate bank borrowings. The technique calculates the fair value by discounting all future interest and principal repayments using a discount rate equal to the Company's borrowing rate at the measurement date. This rate is based on observable inputs of level 2 in the fair value hierarchy, such as market interest rates and inputs concerning the spreads.

As at December 31st, 2018, all borrowings in place are floating rate borrowings.

The Company uses valuation techniques to determine the fair value of its hedging interest rate swaps. These techniques include present value models and incorporate observable inputs of level 2 in the fair value hierarchy, such as interest rate curves and inputs concerning the spreads.

No transfers between levels of the fair value hierarchy have occurred during the financial year 2018.

4.2.4. Prepayments

€ 000		
31 December	2018	2017
Deferred charges		
 Insurance premium 	16	17
 Insurance brokerage 	2	2
 Portal of the board of directors 	13	15
Total	31	33

4.2.5. Cash and cash equivalents

€ 000 31 December	2018	2017
Cash at bank	1,529	1,452
Short-term deposits	-	-
Total	1,529	1,452

Cash and cash equivalents comprise cash at banks and short-term deposits at banks with a maturity of three months or less, which are subject to an insignificant risk of changes in value.

4.2.6. Bank borrowings

Carrying values

€ 000	Non-cı	urrent	Curi	ent	To	tal
31 December	2018	2017	2018	2017	2018	2017
Floating rate borrowings	-90,000	-140,000	-52,500	-52,000	-142,500	-192,000
Fixed rate borrowings	-	_	-	-	_	-
Unamortised balance of debt restructuring						
costs	-	-	-	-	-	-
Accrued interest	-	-	-113	-144	-113	-144
Accrued commitment fees	-	-	-	-		-
Total	-90,000	-140,000	-52,613	-52,144	-142,613	-192,144

At 31^{st} December 2018, the confirmed credit lines of \le 157,0 million were utilised up to \le 142,5 million. The available margin on confirmed credit lines amounted to \le 14,5 million at 31^{st} December 2018. Floating rate borrowings range between 1-month fixed advances and 12-month fixed advances.

Change of outstanding debt throughout 2018

€ 000		Confirmed		Available		
€ 000		lines	Floating	Fix	Total	Available
01/01/2018	Opening	193,000	-192.000	-	-192,000	1,000
15/05/2018	Fixed term reimbursement and closing	-36,000	36,000		36,000	
15/05/2018	Roll-Over credit line advance reimbursement		17,000		17,000	17,000
27/11/2018	New advance		-3,500		-3,500	-3,500
31/12/2018	Closing	157,000	-142,500	-	142,500	14,500

The UCB dividend cashed-in by the Company in May 2018, served to reimburse € 36 million of advances. In May 2018, the Company paid back a credit line of € 36 million contracted in September 2016 and callable during the period covering September 30, 2017 until May 15, 2018.

Contractual maturities

€ 000	Floating	Total
30/06/2019	-52,500	-52,500
30/06/2020	-52,500	-52,500
06/11/2021	-52,000	-52,000
	-157,000	-157,000

The one-off reimbursement of € 36 million as at August 15, 2018 has been financed by dividend income expected from UCB with respect to the 2018 result appropriation. To this contractual reimbursement of € 36 million, it is foreseen that the Company will reimburse an additional € 16 million on a voluntarily basis in the course of 2018.

Collateral

The borrowings are collateralised through a pledge on 4,050,000 UCB shares as at 31 December 2018. The carrying value of these pledged shares amounts to \leq 102,206k.

Covenants

The Company must comply with the following debt covenants:

- Collateral for the bank borrowings must consist of a number of UCB shares, the total market value of which must be at the minimum 157% of the outstanding debt, this ratio equals 202% at 31 December 2018
- Borrowings may not exceed 30% of the fair value of the investment in UCB; as at 31 December 2018, this ratio amounted to 3%
- The solvency ratio (equity versus balance sheet total on a BE GAAP basis) must exceed 70%; as at 31
 December 2018, this ratio equals 90%

Cash flow risk management

Most of the bank borrowings (\leqslant 142,5 million as at 31 December 2018) are structured as roll-over credits with short term floating rate straight drawings. The cash flow risk associated with these borrowings, was, at 31 December 2018, partly covered by an interest rate swap with a notional value of \leqslant 5 million, which effectively converts the portion of the borrowings that corresponds to this notional value, into a fixed rate loan until maturity. Accounting-wise, hedge accounting for this swap and the underlying borrowings has been ceased as per 1 January 2015.

To protect itself against the risk of a future increase in interest rates, the Company has further decided to hedge, as from October 2017 onwards, its entire floating rate debt. The Company has therefore signed, in March 2016, two deferred start swaps that became effective as from 2 October 2017 onwards for notional amounts of respectively \in 82 million and \in 57 million, which will be entirely amortised by mid-May 2021. Both swaps have been designated as hedging instruments for the cash flow risks resulting from floating rate bank borrowings. The effectiveness of the hedge has been documented and hedge accounting is applied.

See note 4.2.7. for more information about the accounting for the swaps.

Borrowing cost

€ 000	2018	2017
Interest expenses	-2,369	-4,591
Commitment fee	-32	-120
Amortisation of debt restructuring costs	-	-393
Change of the clean price of an IRS not designated as hedging instrument (note 4.2.7.)	837	850
Non-effective portion of the hedging IRS (note 4.2.7.)	8	-27
Reclassification adjustments (note 4.2.7.)	-586	-837
Other expenses	-2	-
Total	-2,144	-5,118

Interest expenses on bank borrowings have moved from \leqslant 4,591k in 2017 to \leqslant 2,369k in 2018, reflecting the decrease of the average outstanding debt from \leqslant 206 million in 2017 to \leqslant 157 million in 2018. Thanks to continued favourable market conditions and an active debt management, the average borrowing cost remained stable in 2018 and approximates 1.51% (2.23% in 2017). Interest rates on floating rate borrowings as at December 31, 2018 range between 0.00% and 0.33%.

Commitment fees on the non-utilised part of confirmed credit lines amounted to \leq 32k in 2018 (\leq 120k in 2017). The fee amounts to 0.28% at 31 December 2018.

4.2.7. Derivatives

€000	_	gnated as nstrument	IRS not designed hedging ins	,	Tota	l IRS
31 December	2018	2017	2018	2017	2018	2017
Notional amounts	139,000	139,000	5,000	55,000	144,000	194,000
Full fair value	-709	-870	-180	-2,123	-889	-2,993
Non-current	-318	-532	-	-209	-318	-741
Current	-391	-338	-180	-1,914	-571	-2,252
Accrued interest	-74	-75	-113	-1,219	-187	-1,294
Payable	-74	-75	-113	-1,219	-187	-1,294
Receivable	-	-				
Clean price	-635	-795	-67	-904	-702	-1,699
Clean price, prior year end	-795		-904		-1,699	
Gain/loss(-) during the period, after tax	160		837		997	
Reported in profit or loss	8		251		259	
Gain/loss(-) during the period	8		837		937	
Reclassification adjustment	-		-586		-586	
Reported in other comprehensive						
income	152		586		738	
Gain/loss(-) during the period	152		-		152	
Reclassification adjustment	-		586		586	

As at December 31, 2018, the derivatives as per the accounting records of the Company, consisted of three interest rate swaps (receive floating, pay fix) that were entered into in order to hedge the cash flow risk resulting from floating rate bank borrowings. The outstanding notional amounts of these swaps as at December 31, 2018 are respectively \leq 82 million, \leq 57 million and \leq 5 million.

Swap accounting-wise not designated as hedging instrument – For the initial swap of € 55 million, hedge accounting has been discontinued starting January, 1 2015. Accordingly, all changes in fair value of this swap are recorded in profit or loss. An amount of € 850k has been accounted for in 2017 as a profit (credit to borrowing cost).

The cumulated balance of the clean price as at 1 January 2015 (€ -6,452k) is reclassified from equity to profit or loss (borrowing cost). The portion corresponding to cash flows that are no longer expected to occur (over-hedging) has been immediately charged to profit or loss of the first half of 2015. The remaining balance (€ -5,534k) is reclassified over the remaining lifetime of the swap (until mid 2018) based on the time weighted notional amounts. The amount reclassified during financial year 2018 amounts to € 586k.

The \le 50 million reduction of the notional swap non-designated as a hedging instrument complies with the depreciation table foreseen in the contract.

€ 000	31/12/2018	31/12/2017	Variation
Notional amount	5,000	55.000	-50,000
Full fair value	-180	-2.123	1,943
Accrued interest	-113	-1.219	1,106
Clean price	-67	-904	837

Swaps designated as hedging instruments accounting-wise – It relates to two interest rate swaps with a deferred start at 2 October 2017 for notional amounts of respectively € 82 million and € 57 million. Hedge accounting is applied. Changes in fair value of the swaps (€ 160k) are recorded in other comprehensive income, except for an amount of € 8k corresponding to the ineffective portion of the hedge.

4.2.8. Other creditors

€ 000 31 December	2018	2017
Suppliers and invoices to receive	-104	-80
Non-collected dividends from prior years	-432	-436
Total	-536	-516

The provision for non-collected dividends from prior years has been re-estimated on the basis of the principles set out by the *Commission des Normes Comptables* in its advice 2016/12 related to prescribed liabilities and on the basis of a legal analysis of the applicable prescription rules.

4.3. Income taxes

4.3.1. Deferred tax assets and liabilities

€ 000	Total		Recognised		Unrecognised	
31 December	2018	2017	2018	2017	2018	2017
Derivatives	176	502	-	-	176	502
Unused tax credits	34,814	39,648	-	-	34,814	39,648
Deferred tax assets	34,990	40,123	-	-	34,990	40,123

IAS 12 restricts the recognition of deferred tax assets to the extent that it is probable that taxable profit will be available against which the underlying deductible temporary differences can be utilised. It is 'probable' that there will be sufficient taxable profit if a deferred tax asset can be offset against a deferred tax liability, which will reverse in the same period as the asset, or in a period into which a loss arising from the asset may be carried forward. The deferred tax asset arising from unused tax credits from tax exempt dividends is not recognised, as there is no convincing evidence that sufficient taxable profit will be available against which the unused tax credits can be utilised by the Company. The tax credits do not have a fixed expiry date.

4.3.2. Relationship between tax expense and accounting profit

€ 000	2018	2017
Profit before tax	285,156	266,174
Theoretical income tax rate	29,58%	33.99%
Theoretical income tax	-84,349	-90,473
Reported income tax	-	19,760
Difference between theoretical and reported income tax	-84,349	-110,233
Dividend	-23,762	-26,610
Share of the profit of UCB	85,264	92,532
Tax exempt dividend*	22,770	24,707
Impact of tax reform on UCB reserves	-	19,464
Amortisation of debt restructuring cost	-	133
Net profit on derivatives	77	-293
Others	-	-300
Total effects of difference between theoretical and reported tax	84, 349	110,233

^{*}limited to the statutory profit of the Company

4.4. General and administrative expenses

€ 0	00	2018	2017
Dire	ectors' remuneration	341	337
Atte	Attendance fee		46
Gen	eral manager remuneration	96	173
Stat	cutory auditors' fee	12	11
Serv	vice providers		
-	Bookkeeping	84	44
-	Advise (legal, tax, social, financial, insurance)	73	79
-	Notary public	3	
-	Paying agent	10	
Con	tributions		
-	Euronext	51	48
-	Euroclear	15	15
-	FSMA	57	59
-	Others	3	15
Serv	vices		
-	Financial publicity	44	34
-	Insurance	33	33
-	Board portal	15	9
-	Training		
Mis	cellaneous (post, bank, office supplies, travel,)	29	12
Gift		20	25
VAT			
Tot	al	951	940

4.5. Earnings per share

As there are no instruments with potential dilutive effect, basic and dilutive earnings per share are the same. They are calculated by dividing the profit by the weighted average number of shares in issue during the year. Throughout the financial year 2018, the number of subscribed shares still amounts to 44,548,598. The weighted average amount of shares circulating throughout financial year 2018 is slightly different in spite of the acquisition of 36.000 own shares and amounts to 44.545.598 shares.

Within the framework of the autorization from the extraordinary general meeting (held on April 25^{th} 2018), the Board of Directors of Financière de Tubize has acquired, on the 26^{th} of November 2018, 36.000 own shares at a price of €59 per share, adding up to 0.081% of shares representing the firm's capital. The Board of Directors has deemed the acquisition of such shares, transaction that occurred outside of the regulated market, to be an interesting opportunity considering the offered price. The Board of Directors then decided, on the 14^{th} of December 2018, to proceed to the cancellation of the 36.000 own shares the firm owned. The shares have been cancelled on January 30^{th} 2019. Therefore, the firm does no longer own "own shares" and the amount of shares representing the firm's capital is reduced from 44,548,598 shares to 44,512,598.

4.6. Dividends

In respect of the accounting year 2018, a proposal to pay a gross dividend of \leqslant 0.56 per share, or a total amount of \leqslant 24,9 million, will be submitted for approval to the shareholders meeting of 24 April 2019. In accordance with IAS 10, the proposed dividend has not been recognised as a liability at year-end.

4.7. Capital management

For the purpose of the Company's capital management, capital includes issued capital, share premium and all other equity reserves disclosed in the statement of changes in equity.

The issued share capital of the Company amounts to € 235 million and is fully paid up. The share premium reserve amounts to 1,225k. The share capital at 31 December 2018 is represented by 44,548,598 shares, unchanged compared to 31 December 2017. The number of registered shares was 33,751,038 at 31 December 2018; the remainder of the shares are de-materialised. The holders of the shares are entitled to receive dividends as declared. They have one vote per share at the shareholders meeting. Included in the total number of shares are zero shares that represent a reserve for exchanging against attribution rights, both issued or in reserve for issue; these reserve shares do not give right to dividend or voting.

The Company manages its capital structure in light of its participating interest in UCB and its indebtedness. The Company's capital management aims to ensure that it meets all financial covenants. Breaches in meeting the financial covenants would permit the bank to immediately call its borrowings. There have

been no breaches in the financial covenants during the financial years ended 31 December 2018 and 2017. See also note 4.2.6. for more information on the nature and the calculation of the covenants.

4.8. Related parties' transactions

Shareholders

On the basis of the transparency and leaders' declarations notified to the Company, the shareholders structure at 31 December 2018 can be summarised as follows:

	In concert		Outside concert		Total	
	Number	%	Number	%	Number	%
Financière Eric Janssen SPRL	8,525,014	19.14%	1,988,800	4.46%	10,513,814	23.60%
Daniel Janssen	5,881,677	13.20%	-	-	5,881,677	13.20%
Altaï Invest SA	4,969,795	11.16%	26,468	0.06%	4,996,263	11.22%
Barnfin SA	3,903,835	8.76%	-	-	3,903,835	8.76%
Jean van Rijckevorsel	11,744	0.03%	-	-	11,744	0.03%
Total voting rights held by the						
reference shareholders	23,292,065	<i>52.29%</i>	2,015,268	4.52%	25,307,303	56.81%
Other shareholders	-	-	19,241,265	43.19%	19,241,265	43.19%
Total voting rights	23,292,065	52.29%	21,256,533	47.71%	44,548,598	100.00%

Altaï Invest is controlled by Evelyn du Monceau. Barnfin is controlled by Bridget van Rijckevorsel.

The reference shareholders act in concert. The terms of the concert are laid down in a shareholders agreement. The key elements of this agreement can be summarised as follows:

- The objective of the concert is to ensure, through Financière de Tubize, the stability of the shareholder structure of UCB in view of the long-term industrial development of the latter. In this perspective, it aims at preserving the predominance of the family shareholder structure of Financière de Tubize.
- The parties to the concert consult with each other about the decisions to be taken at the general meeting of Financière de Tubize, and try, to the extent possible, to reach a consensus. They ensure that they are properly represented at the board of directors of Financière de Tubize. Within this board and through their representatives at the board of directors of UCB, they consult with each other about the significant strategic decisions concerning UCB, and try, to the extent possible, to reach a consensus.
- The parties inform each other prior to any project of significant acquisition or sale of shares of Financière de Tubize; pre-emption rights and tag along are also in place within the family.

The reference shareholders and the persons closely related to them have no direct or indirect relationships with the Company other than those resulting from their capacity as shareholder or, when applicable, their representation in the board of directors.

Directors

The short-term benefits attributed to the directors (10 directors and the general manager) amount to € 485k in total for the financial year 2018. The directors did not benefit from any other type of remuneration during the year 2018.

UCB

In 2018, the Company has received a dividend from UCB in relation to accounting year 2017 for a total amount of \leqslant 80,331k. There have been no other transactions with UCB during the year 2018.

Commissaires

Auditor

In 2018, the auditor fees amount to \leq 13,3k, to breakdown between the audit engagement (\leq 12,1k) and the other missions (\leq 1,2k).